Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins
- 1 December 2019
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 865, 172803
Abstract
No abstract availableKeywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (216S304)
- Université de Montpellier
- Medizinische Fakultät, Universität Leipzig
This publication has 21 references indexed in Scilit:
- A large deletion of the AVPR2 gene causing severe nephrogenic diabetes insipidus in a Turkish familyEndocrine, 2013
- Vasopressin Type 2 Receptor V88M Mutation: Molecular Basis of Partial and Complete Nephrogenic Diabetes InsipidusNephron Physiology, 2009
- Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes InsipidusJournal of the American Society of Nephrology, 2006
- Molecular Biology of Hereditary Diabetes InsipidusJournal of the American Society of Nephrology, 2005
- Disease‐causing V2 Vasopressin Receptors are Retained in Different Compartments of the Early Secretory PathwayTraffic, 2004
- Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 ReceptorsJournal of Biological Chemistry, 2004
- Quality control in the endoplasmic reticulum protein factoryNature, 2003
- Therapeutic approaches to protein-misfolding diseasesNature, 2003
- Molecular and cellular defects in nephrogenic diabetes insipidusPediatric Nephrology, 2001
- MOLECULAR BIOLOGY OF DIABETES INSIPIDUSAnnual Review of Medicine, 1995